GlassScriptPhysician profile
Wesley S Hilger
NPI 1144205634
$3,355.98
in general payments reported to CMS, 2019-2025
26 companies · $439 in 2025
The $439 reported for 2025 was less than what a typical Urogynecology and Reconstructive Pelvic Surgery (Urology) provider received nationally (typical 2025 total: $782).
See the full distribution for Urogynecology and Reconstructive Pelvic Surgery (Urology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,061 · 2020: $445 · 2021: $641 · 2022: $232 · 2023: $354 · 2024: $184 · 2025: $439.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $948 · Gift: $28.88.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $948.19 |
| Gift | $28.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $536.56 | 2019-2021 | |
| Pfizer INC. | $440.28 | 2019-2022 | |
| Abbvie INC. | $249.04 | 2019-2025 | |
| Amag Pharmaceuticals, INC. | $235.96 | 2019-2020 | |
| Hologic Sales and Service, LLC | $217.66 | 2019-2025 | Aptima |
| Astellas Pharma US INC | $212.24 | 2019-2023 | Myrbetriq, Veozah |
| Coloplast Corp | $206.29 | 2019-2024 | |
| Sumitomo Pharma America, INC. | $173.16 | 2023-2024 | Gemtesa |
| Femselect INC. | $172.94 | 2025 | Enplace |
| Boston Scientific Corporation | $171.41 | 2021-2025 | Upsylon, Axonics, Solyx Sis System |
| Therapeuticsmd, INC. | $129.31 | 2019-2022 | |
| Urovant Sciences INC | $105.31 | 2021-2022 | |
| Axonics, INC. | $92.02 | 2021-2022 | |
| Coopersurgical, INC. | $90.47 | 2019 | |
| Vertex Pharmaceuticals Incorporated | $48.91 | 2025 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Caldera Medical, INC | $45.04 | 2023-2025 | Desara |
| C. R. Bard, INC. & Subsidiaries | $40.54 | 2019 | |
| Laborie Medical Technologies Corp. | $37.51 | 2024-2025 | Eclipse |
| Ethicon US, LLC | $28.69 | 2025 | Vistaseal |
| Convatec INC. | $22.12 | 2019 | |
| Mayne Pharma Commercial LLC | $20.51 | 2025 | |
| Shield Therapeutics INC | $17.86 | 2024 | |
| Rochester Medical Corporation | $17.48 | 2021 | |
| Myovant Sciences INC. | $16.35 | 2021 | |
| Baxter Healthcare | $15.26 | 2019 | |
| Dentsply Ih Ab | $13.06 | 2023 | Lofric |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wesley Hilger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.